- Activity pressure is positive on the latest completed week.
MANGALAM
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Mangalam Drugs & Organics Limited · Healthcare · Drug Manufacturers - Specialty & Generic
Latest close
27.19 INR
0.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -11.9% below the Trend Line and sits at 6.8% of its 52-week range. The latest completed week returned 0.3%, after a -2.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.
Setup score
24
out of 100
Latest Close
27.19 INR
7 Aug 2026
1W Return
0.3%
latest completed week
4W Return
-2.0%
short-term follow-through
12W Return
-9.2%
quarterly tape
Trend Breadth
0.0%
0 of 52 weeks active
Volume Ratio
1.3x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 39.43% based on similar historical setup states.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
0.3%
Latest completed week; four-week move -2.0%.
Indicator stack
0/53
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 39.43%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
51/100
25 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -11.9% below the Trend Line and sits at 6.8% of its 52-week range. The latest completed week returned 0.3%, after a -2.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.3x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0112-week average 0.04
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -2.0% over four weeks, -9.2% over 12 weeks, and -64.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure0.39Latest activity-pressure read.
Pressure change-53.7%Four-week change in activity pressure.
Leadership-34.45Latest relative-leadership reading.
RS change10.8%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 82%
Model confidence 77%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality49/100Profitability and accounting quality. Underlying universe rank 52; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- 0.2x Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -5.2% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 31.7% Gross profit retained from each unit of revenue.
- Operating margin
- -14.0% Operating profit retained from revenue.
- Free-cash-flow margin
- -3.3% Free cash flow generated from revenue.
- Return on invested capital
- -11.8% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- -26.9% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- -134.5% Latest one-year free-cash-flow growth.
- Piotroski F-score
- 4/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -7.4x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 25 relevant articles.
3 positive · 20 neutral · 2 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-68.7%Distance below the 52-week high.
13-week volatility2.4%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher7 of 2619 weeks finished lower.
Best week+10.9%Week of 6 Mar.
Worst week-8.5%Week of 13 Feb.
Latest week+0.3%Week of 7 Aug.
Shape of recent returns
Strong gains4
Modest gains3
Flat weeks0
Modest losses12
Sharp losses7
Recent vol2.4%13-week weekly-return volatility.
Base vol10.2%52-week weekly-return volatility.
Up/down split15/37Count of positive and negative weeks in the 52-week window.
Average skew8.6% / -5.5%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Drug Manufacturers - Specialty & Generic
4-week rank54 / 92
Group average1.0%
Trend breadth76.1%
Trend76.1%active weekly trend signals
MD80.4%positive activity pressure
RS65.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape21/100
Trend, activity pressure, participation, and risk combine to a 21/100 tape read.
Indicator analysis29/100Latest 12-week confirmation: trend 0/12, activity pressure 12/12, relative leadership 0/12.
Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 39.43%Next-week expectancy is negative with a 39.43% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 14 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 25 relevant articles.
Mangalam Cement cuts Scope 1 emissions 9.1% in FY26 BRSR filing Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 27.19 INR | 0.3% | 30.88 INR | 82.20 INR | 0.39 | -34.45 | 105.9K | Off |
| 31 Jul 2026 | 27.11 INR | -0.4% | 31.26 INR | 82.70 INR | 0.61 | -35.66 | 84.2K | Off |
| 24 Jul 2026 | 27.22 INR | -1.3% | 31.37 INR | 83.23 INR | 0.71 | -35.52 | 80.1K | Off |
| 17 Jul 2026 | 27.59 INR | -0.6% | 31.25 INR | 83.77 INR | 0.76 | -37.81 | 103.2K | Off |
| 10 Jul 2026 | 27.75 INR | -1.2% | 31.13 INR | 84.28 INR | 0.84 | -38.63 | 164.9K | Off |
| 3 Jul 2026 | 28.09 INR | -2.4% | 31.05 INR | 84.80 INR | 0.76 | -39.45 | 112.1K | Off |
| 26 Jun 2026 | 28.79 INR | -4.1% | 30.97 INR | 85.32 INR | 0.68 | -38.73 | 0 | Off |
| 19 Jun 2026 | 30.03 INR | 6.6% | 30.94 INR | 85.83 INR | 0.64 | -37.17 | 29.4K | Off |
| 12 Jun 2026 | 28.18 INR | -1.1% | 31.48 INR | 86.34 INR | 0.59 | -41.16 | 19.3K | Off |
| 5 Jun 2026 | 28.50 INR | -0.9% | 32.62 INR | 86.87 INR | 0.60 | -41.00 | 13.6K | Off |
| 29 May 2026 | 28.76 INR | -2.2% | 33.78 INR | 87.36 INR | 0.57 | -42.00 | 101.1K | Off |
| 22 May 2026 | 29.41 INR | -1.8% | 35.00 INR | 87.84 INR | 0.40 | -42.17 | 147.3K | Off |
| 15 May 2026 | 29.95 INR | -1.2% | 36.30 INR | 88.35 INR | 0.05 | -41.98 | 86.0K | Off |
| 8 May 2026 | 30.32 INR | 2.8% | 37.64 INR | 88.85 INR | -0.18 | -43.57 | 118.2K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.